Search

Your search keyword '"Drug Resistance, Neoplasm physiology"' showing total 187 results

Search Constraints

Start Over You searched for: Descriptor "Drug Resistance, Neoplasm physiology" Remove constraint Descriptor: "Drug Resistance, Neoplasm physiology" Topic lung neoplasms Remove constraint Topic: lung neoplasms
187 results on '"Drug Resistance, Neoplasm physiology"'

Search Results

1. Targeting metabolic adaptive responses induced by glucose starvation inhibits cell proliferation and enhances cell death in osimertinib-resistant non-small cell lung cancer (NSCLC) cell lines.

2. Circ_0001658 regulates gefitinib resistance of non-small cell lung cancer through miR-409-3p/TWIST1 axis.

3. Cisplatin resistance of NSCLC cells involves upregulation of visfatin through activation of its transcription and stabilization of mRNA.

4. Circular RNA circ-RNF121 contributes to cisplatin (DDP) resistance of non-small-cell lung cancer cells by regulating the miR-646/SOX4 axis.

5. A review of research progress on mechanisms and overcoming strategies of acquired osimertinib resistance.

6. Drug resistance of targeted therapy for advanced non-small cell lung cancer harbored EGFR mutation: from mechanism analysis to clinical strategy.

7. HER2 mediates clinical resistance to the KRAS G12C inhibitor sotorasib, which is overcome by co-targeting SHP2.

8. Potential Role of GST- π in Lung Cancer Stem Cell Cisplatin Resistance.

9. Identification and Characterization of Senescence Phenotype in Lung Adenocarcinoma with High Drug Sensitivity.

10. TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small-cell lung cancer.

11. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.

12. CUL4 high Lung Adenocarcinomas Are Dependent on the CUL4-p21 Ubiquitin Signaling for Proliferation and Survival.

13. Beyond Single-Cell Analysis of Metallodrugs by ICP-MS: Targeting Cellular Substructures.

14. Identification of microRNAs that promote erlotinib resistance in non-small cell lung cancer.

15. [Progress in Single-cell RNA Sequencing of Lung Adenocarcinoma].

16. NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells.

17. Endogenous glutamate determines ferroptosis sensitivity via ADCY10-dependent YAP suppression in lung adenocarcinoma.

18. Exosomes-transmitted miR-7 reverses gefitinib resistance by targeting YAP in non-small-cell lung cancer.

19. Mechanisms of resistance to chemotherapy in non-small cell lung cancer.

20. Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer.

21. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2.

22. Matrine Inhibitory Effect on Self-renewal and Re-sensitization of 5-FU Resistant NSCLC Stem Cells were through Let-7b dependent Downregulation of CCND1.

23. Clinical significance of transcription factor RUNX2 in lung adenocarcinoma and its latent transcriptional regulating mechanism.

24. Hypoxia Induces Resistance to EGFR Inhibitors in Lung Cancer Cells via Upregulation of FGFR1 and the MAPK Pathway.

25. Effects of microRNA regulation on antiangiogenic therapy resistance in non-small cell lung cancer.

26. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.

27. Reelin Promotes Cisplatin Resistance by Induction of Epithelial-Mesenchymal Transition via p38/GSK3β/Snail Signaling in Non-Small Cell Lung Cancer.

28. Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance.

29. [Immunotherapy of metastatic non-small cell lung cancer from first line to resistance and its management].

30. Evaluation of nuclear NF-κB, transglutaminase2, and ERCC1 as predictors of platinum resistance in testicular tumors.

31. Activation of notch 3/c-MYC/CHOP axis regulates apoptosis and promotes sensitivity of lung cancer cells to mTOR inhibitor everolimus.

32. A novel histone acetyltransferase inhibitor A485 improves sensitivity of non-small-cell lung carcinoma cells to TRAIL.

33. Influence of nonprotective autophagy and the autophagic switch on sensitivity to cisplatin in non-small cell lung cancer cells.

34. ROS1-rearranged Non-small Cell Lung Cancer.

35. Epidermal Growth Factor Receptor Mutations.

36. β-Adrenergic Signaling in Lung Cancer: A Potential Role for Beta-Blockers.

37. Licochalcone D Induces ROS-Dependent Apoptosis in Gefitinib-Sensitive or Resistant Lung Cancer Cells by Targeting EGFR and MET.

38. FGFRL1 affects chemoresistance of small-cell lung cancer by modulating the PI3K/Akt pathway via ENO1.

39. Cx32 mediates norepinephrine-promoted EGFR-TKI resistance in a gap junction-independent manner in non-small-cell lung cancer.

40. Olean-28,13b-olide 2 plays a role in cisplatin-mediated apoptosis and reverses cisplatin resistance in human lung cancer through multiple signaling pathways.

41. Transmembrane-4 L-six family member-1 (TM4SF1) promotes non-small cell lung cancer proliferation, invasion and chemo-resistance through regulating the DDR1/Akt/ERK-mTOR axis.

42. HOXB13 networking with ABCG1/EZH2/Slug mediates metastasis and confers resistance to cisplatin in lung adenocarcinoma patients.

43. Erlotinib for Patients with EGFR Wild-Type Metastatic NSCLC: a Retrospective Biomarkers Analysis.

44. Palbociclib overcomes afatinib resistance in non-small cell lung cancer.

45. The lung microenvironment: an important regulator of tumour growth and metastasis.

46. Epithelial-mesenchymal transition (EMT) beyond EGFR mutations per se is a common mechanism for acquired resistance to EGFR TKI.

47. EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer.

48. RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.

49. β-catenin decreases acquired TRAIL resistance in non-small-cell lung cancer cells by regulating the redistribution of death receptors.

50. Triptolide enhances chemotherapeutic efficacy of antitumor drugs in non-small-cell lung cancer cells by inhibiting Nrf2-ARE activity.

Catalog

Books, media, physical & digital resources